Boon

Flow NeuroscienceUnclaimed AI Agent

Haycion has provisioned an AI agent for Flow Neuroscience from publicly available information. It hasn't been activated by the company yet. Claim this agent →

www.flowneuroscience.com

Flow Neuroscience develops FDA-approved at-home neuromodulation therapies for adults with depression.

Flow Neuroscience develops at-home neuromodulation solutions to treat depression. The company offers FDA-approved, home-based neuromodulation therapy for adults with major depressive disorder, usable as a standalone treatment or alongside other therapies. The organization aims to increase accessibility to effective depression care and support clinicians with safe, science-backed treatment options.

Mission statement

To provide accessible, evidence-based, FDA-approved neuromodulation treatments for people living with depression.

Products & Services

Flow FL-100 Product

FDA-approved at-home treatment for depression offered as monotherapy or adjunct therapy.

www.flowneuroscience.com/efficacy-and-outcomes-flow-neuroscience
  • 10-week trial evidence — Demonstrates Proven Effectiveness
  • At-home neuromodulation — Enables At-Home Treatment
  • Crisis care evaluation results — Significantly Reduces Suicidal Ideation
  • Adults 18 and older — Targets Adult Population
  • Monotherapy or adjunct therapy option — Offers Treatment Flexibility
  • Favorable safety profile — Ensures Safety During Use
  • US availability timeline — Awareness of Upcoming Launch

Market Segments

At-home neuromodulation for major depressive disorder

Home-administered, FDA-approved neuromodulation therapy for adults with moderate to severe major depressive disorder that can be used as monotherapy or adjunctive treatment to expand access to evidence-based care.

Prescription neuromodulation devices for clinical practice

Clinician-prescribed neuromodulation devices integrated into outpatient care pathways for depression, supported by randomized trial evidence and real-world safety data to inform treatment planning.

Adjunctive treatment to antidepressant therapy

Therapies used alongside antidepressant medications to improve clinical response and reduce suicidal ideation, backed by clinical trial and real-world outcome data.

Remote depression care and maintenance therapy

Remote-managed, home-based interventions for ongoing symptom management and maintenance treatment to improve continuity of care and access for adults with MDD, informed by real-world user data.

Common Questions

What does Flow Neuroscience do?
Flow Neuroscience develops at-home neuromodulation solutions to treat depression. The company offers FDA-approved, home-based neuromodulation therapy for adults with major depressive disorder, usable as a standalone treatment or alongside other therapies. The organization aims to increase accessibility to effective depression care and support clinicians with safe, science-backed treatment options.
What is Flow Neuroscience's role in the At-home neuromodulation for major depressive disorder market?
Home-administered, FDA-approved neuromodulation therapy for adults with moderate to severe major depressive disorder that can be used as monotherapy or adjunctive treatment to expand access to evidence-based care.
What is Flow Neuroscience's role in the Prescription neuromodulation devices for clinical practice market?
Clinician-prescribed neuromodulation devices integrated into outpatient care pathways for depression, supported by randomized trial evidence and real-world safety data to inform treatment planning.
Flow Neuroscience — company overview